Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aim to compare immunogenicity of the inactivated H5 influenza vaccine single dose between subjects previously vaccinated with LAIV H5N2 and naïve subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais

NCT01666262

Healthy

COMPLETED PHASE1/PHASE2

Safety and Immunogenicity of Live Attenuated Influenza H5N2

NCT01841918

Influenza Due to Influenza A Virus Subtype H5N2

COMPLETED PHASE2

Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers

NCT01656356

Preventive Avian Flu

COMPLETED PHASE1

Immunogenicity of H5N1 Vaccine Following H5N2

NCT02153671

Influenza Vaccine

COMPLETED PHASE2

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

NCT05284851

Influenza Prevention

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is a non-randomized, open label study to evaluate a licensed OrniFlu® inactivated vaccine (produced by Microgen Russia) which will be given to healthy adult volunteers who participated in a double blind placebo-controlled study Protocol No.: GPO AVIAN FLU Vaccine-V02-2 at Vaccine Trial Centre and Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University in February to May 2013.

A total of 60 subjects, of whom 40 received two doses of LAIV H5N2 (prime-boost group), and 20 received placebo (control group) in the previous study will be asked to return to the clinic to receive a single dose of an inactivated H5 influenza vaccine.

Total foloww up is 90 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Avian Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OrniFlu® inactivated vaccine

Group Type EXPERIMENTAL

OrniFlu® inactivated vaccine

Intervention Type BIOLOGICAL

All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OrniFlu® inactivated vaccine

All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participated in the Phase II study Protocol No.: GPO AVIAN FLU Vaccine-V02-2
* Healthy
* Age 18-49 years old
* Having Thai ID card or equivalent
* Anti HIV - Negative
* All hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not higher than 1.5 time of normal value without any clinical finding from history and physical examination)
* Able to read and write and sign written informed consent.

Exclusion Criteria

* Known history of egg allergy
* Having had recently influenza infection confirmed as H5
* Receiving other vaccination against H5N1
* History of bronchial asthma
* History of chronic lung diseases
* History of chronic rhinitis
* History of immunodeficiency state
* History of immunosuppression\< 6 months prior to immunization
* History of heavy smoking (more than 5 packs per day)
* History of alcoholic (pure drink 200 ml per day)
* Acute infectious and noninfectious diseases (within 2 weeks)
* HIV positives
* The volunteers who have been taking immunoglobulin products or have had a blood transfusion during past three months before the beginning of the experiment
* Participation in other research study or stop participant less than 1 month
* Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding
* Poultry workers

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes